



The Role of Radiation in Cancer Treatment: New Insights towards Personalized Therapies

Guest Editors:

Dr. Luigi Minafra

National Research Council (CNR)
—Institute of Bioimaging and
Complex Biological Systems
(IBSBC), Cefalù, PA, Italy

**Dr. Francesco Paolo
Cammarata**

National Research Council (CNR),
Institute of Bioimaging and
Molecular Physiology (IBFM),
Cefalù, PA, Italy

Dr. Marco Calvaruso

National Research Council (CNR),
Institute of Bioimaging and
Molecular Physiology (IBFM),
Cefalù, PA, Italy

Deadline for manuscript
submissions:

closed (15 December 2021)

Message from the Guest Editors

Dear Colleagues,

At present, radiation therapy (RT) remains an essential component of multimodality approaches for the treatment of many types of cancer, and one of the most effective cancer therapies. Currently, clinical practice still offers standard RT protocols for patients with cancer affecting the same organ, without considering the molecular profile and the tumoral histotype, which may affect the RT outcome. Unfortunately, RT does not always lead to therapeutic benefits, due to distant metastatic spread and local recurrence, which induce radioresistance. Indeed, tumor radiosensitivity depends on many factors, some of which are linked to the clinical state and genetic background of the patient. This Special Issue aims to provide new insights into the role of RT in different types of cancer in order to develop personalized therapies, and it will also highlight the use of combined approaches with new targeted agents. Other topics of interest to this Special Issue will be the discovery and analysis of radioresponse biomarkers reported by different in vitro, in vivo, or clinical studies.

Dr. Luigi Minafra

Dr. Francesco Paolo Cammarata

Dr. Marco Calvaruso

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)